Premium
Prospective study of home use of mifepristone and misoprostol for medical abortion up to 10 weeks of pregnancy in Kazakhstan
Author(s) -
Platais Ingrida,
Tsereteli Tamar,
Grebennikova Galina,
Lotarevich Tatyana,
Winikoff Beverly
Publication year - 2016
Publication title -
international journal of gynecology and obstetrics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.895
H-Index - 97
eISSN - 1879-3479
pISSN - 0020-7292
DOI - 10.1016/j.ijgo.2016.02.018
Subject(s) - misoprostol , medicine , mifepristone , medical abortion , abortion , obstetrics , pregnancy , gynecology , outpatient clinic , abortifacient , vacuum aspiration , family planning , population , research methodology , genetics , environmental health , biology
Objective To evaluate the efficacy of at‐home medical abortion in Kazakhstan. Methods A comparative, non‐randomized study was undertaken at three clinics in Kazakhstan between October 10, 2013, and November 27, 2014. Women who sought medical abortion and had an intrauterine pregnancy of up to 70 days were enrolled. All participants took 200 mg mifepristone followed by 600 μg sublingual misoprostol 24–48 hours later. Women were offered the choice to take mifepristone at the clinic or at home; all took misoprostol at home. Abortion completion was assessed at an in‐clinic follow‐up appointment scheduled for all participants 2 weeks after mifepristone administration. Results Of 290 enrolled women, 185 (63.8%) chose to self‐administer mifepristone at home. Three (1.0%) of 289 women included in outcome analyses required surgical intervention for incomplete abortion. Therefore, the overall success rate was 99.0% (95% confidence interval 97.0%–99.7%). No serious adverse events occurred. Conclusion Outpatient medical abortion with mifepristone and misoprostol is safe and effective up to 70 days of pregnancy. This service should be offered to women in Kazakhstan. ClinicalTrials.gov : NCT02018796